

Ishwaria M Subbiah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2758078/publications.pdf>

Version: 2024-02-01

64
papers

1,236
citations

471509

17
h-index

395702

33
g-index

65
all docs

65
docs citations

65
times ranked

2278
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2239-2245.	1.6	104
2	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 313-319.	27.6	103
3	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. <i>Trends in Cancer</i> , 2020, 6, 181-191.	7.4	82
4	Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents. <i>Oncologist</i> , 2011, 16, 1120-1130.	3.7	80
5	STUMP unâ€œstumpedâ€œ anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , 2015, 8, 66.	17.0	75
6	Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 85, 197-203.	1.9	72
7	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. <i>Supportive Care in Cancer</i> , 2021, 29, 2821-2840.	2.2	65
8	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015, 89, 76-79.	2.0	58
9	Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. <i>Supportive Care in Cancer</i> , 2019, 27, 3729-3737.	2.2	53
10	Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers. <i>ESMO Open</i> , 2020, 5, e000862.	4.5	41
11	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. <i>Oncotarget</i> , 2013, 4, 153-162.	1.8	31
12	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018, 118, 763-769.	6.4	28
13	Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. <i>Journal of Geriatric Oncology</i> , 2020, 11, 451-454.	1.0	28
14	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. <i>European Journal of Cancer</i> , 2020, 136, 176-185.	2.8	27
15	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 930.e1-930.e10.	1.2	24
16	Current update on gallbladder carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 2474-2489.	2.1	23
17	Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. <i>JCO Oncology Practice</i> , 2022, 18, 140-147.	2.9	23
18	Rapid Transition to Virtual Care during the COVID-19 Epidemic: Experience of a Supportive Care Clinic at a Tertiary Care Cancer Center. <i>Journal of Palliative Medicine</i> , 2021, 24, 1467-1473.	1.1	21

#	ARTICLE	IF	CITATIONS
19	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017, 4, 47-56.	2.2	21
20	Convergence of Geriatrics and Palliative Care to Deliver Personalized Supportive Care for Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2185-2194.	1.6	18
21	Performance Status Restriction in Phase III Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1322-1326.	4.9	18
22	Exceptional responders: in search of the science behind the miracle cancer cures. <i>Future Oncology</i> , 2015, 11, 1-4.	2.4	17
23	Association of Edmonton Symptom Assessment System Global Distress Score With Overall Survival in Patients With Advanced Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117295.	5.9	14
24	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , 2014, 5, 6584-6593.	1.8	14
25	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 389-397.	2.3	13
26	Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future. <i>Current Treatment Options in Oncology</i> , 2014, 15, 41-54.	3.0	13
27	Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1324-1328.	1.0	13
28	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151216.	1.5	13
29	A Big World Made Small: Using Social Media to Optimize Patient Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e212-e218.	3.8	11
30	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. <i>Annals of Hematology</i> , 2013, 92, 1149-1149.	1.8	9
31	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015, 6, 28453-28462.	1.8	9
32	Incidence, Nature, and Consequences of Oncologists' Experiences With Sexual Harassment. <i>Journal of Clinical Oncology</i> , 2022, 40, 1186-1195.	1.6	9
33	Development of a Patient-Centered Framework for Oncology Clinicians to Address Uncertainty in Cancer Care During the COVID-19 Pandemic. <i>Current Treatment Options in Oncology</i> , 2020, 21, 99.	3.0	8
34	A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 135-142.	0.8	8
35	The Evolution of Geriatric Oncology and Geriatric Assessment over the Past Decade. <i>Seminars in Radiation Oncology</i> , 2022, 32, 98-108.	2.2	8
36	Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017, 140, 208-215.	5.1	7

#	ARTICLE	IF	CITATIONS
37	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. <i>ESMO Open</i> , 2021, 6, 100079.	4.5	7
38	Social Media and Professional Development for Oncology Professionals. <i>JCO Oncology Practice</i> , 2022, 18, 566-571.	2.9	7
39	Healthcare Disparities and the COVID-19 Pandemic: Analysis of Primary Language and Translations of Visitor Policies at NCI-Designated Comprehensive Cancer Centers. <i>Journal of Pain and Symptom Management</i> , 2021, 61, e13-e16.	1.2	6
40	Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. <i>Oncologist</i> , 2019, 24, 1291-1293.	3.7	5
41	Use of Peripheral μ -Opioid Receptor Antagonists for Treating Opioid-Induced Constipation among US Medicare Beneficiaries from 2014 to 2018. <i>Journal of Palliative Medicine</i> , 2021, 24, 1236-1239.	1.1	5
42	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. <i>JCO Oncology Practice</i> , 2022, 18, e442-e451.	2.9	5
43	Bringing wearable devices into oncology practice: fitting smart technology in the clinic. <i>Discovery Medicine</i> , 2018, 26, 261-270.	0.5	5
44	Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma. <i>Hepatology</i> , 2010, 52, 1524-1524.	7.3	4
45	Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials. <i>Cancers</i> , 2020, 12, 2636.	3.7	4
46	Visitation policies at NCI-designated comprehensive cancer centers during the COVID-19 pandemic. <i>Supportive Care in Cancer</i> , 2021, 29, 4895-4898.	2.2	4
47	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018, 9, 28842-28848.	1.8	4
48	Development of a strategic plan for the dissemination and communication of aging research through the Cancer and Aging Research Group (CARG) infrastructure grant. <i>Journal of Geriatric Oncology</i> , 2020, 11, 359-360.	1.0	3
49	Integration of End-of-Life Care into Accountable Care Organization's Quality Measures. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 877-878.	2.6	2
50	Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 42-45.	1.6	2
51	Development of a Regulatory Framework Governing Health Care Interactions on Social Media Platforms. <i>JCO Oncology Practice</i> , 2022, 18, 529-532.	2.9	2
52	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012, 59, 960-4.	0.5	2
53	Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. <i>Journal of Geriatric Oncology</i> , 2019, 10, 998-1002.	1.0	1
54	Mentoring pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 335-337.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Abstract 4700: One size does not fit all: Fingerprinting advanced carcinoma of unknown primary through comprehensive profiling identifies aberrant activation of the PI3K and MAPK signaling cascades in concert with impaired cell cycle arrest. , 2014, , .		1
56	Perspectives on geriatric oncology research presented at the 2019 San Antonio Breast Cancer Symposium. Journal of Geriatric Oncology, 2020, 11, 740-744.	1.0	0
57	Advances in cancer research dissemination through the pandemic and beyond. Annals of Oncology, 2021, 32, 689-693.	1.2	0
58	Highlighting selected research conducted in older patients presented at the 23rd European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (2021): Young International Society of Geriatric Oncology Report. Journal of Geriatric Oncology, 2022, 13, 4-6.	1.0	0
59	Abstract 1751: A phase I study of lenalidomide in combination with bevacizumab, sorafenib, temsirolimus, or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in patients with advanced cancers. , 2012, , .		0
60	Abstract 2669: Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience. , 2012, , .		0
61	Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials. , 2015, , .		0
62	Abstract 604: Impaired cell cycle arrest with concurrent epigenetic deregulation identified through next generation sequencing in patients with advanced carcinoma of unknown primary: Implications for personalized medicine. , 2015, , .		0
63	Abstract 3997: Outcomes of geriatric sarcoma patients enrolled in phase 1 clinical trials. , 2019, , .		0
64	Multidimensional impact of the geriatric assessment in the cancer care of older adults. Cancer, 2021, , .	4.1	0